FDA Brief

Warning letters Drugs

FDA warning letter to

Green Wave Analytical, LLC

High riskIssued Aug 19, 2022Posted Aug 30, 2022Division of Pharmaceutical Quality Operations IV

FDA warned Green Wave Analytical, a contract drug testing lab, over quality violations and its denied inspection access.

What happened

FDA inspected Green Wave Analytical's San Diego contract testing laboratory from February 15 to March 7, 2022. FDA found that the firm tested drugs, including sterile injectables, without validating methods, with incomplete records and inadequate computer controls, and without proper environmental monitoring for sterility testing, under current good manufacturing practice (CGMP) requirements. For the first three days, the firm denied access to its registered Suite B and falsely said it did not perform CGMP drug testing.

What FDA found

  1. The firm did not validate or verify test methods, including its phenobarbital sodium assay and sterility, endotoxin, and other microbial tests.

    21 CFR 211.165(e)
  2. Laboratory records lacked key details such as the method used, standards, reagents, sample lot number, and equipment.

    21 CFR 211.194(a)
  3. HPLC computer systems lacked controls to prevent data deletion or alteration, had no active audit trail, no secure backup, and unvalidated electronic signatures.

    21 CFR 211.68(b)
  4. The firm did not monitor environmental conditions or personnel for sterility testing and lacked adequate facilities and controls for aseptic testing.

    21 CFR 211.42(c)(10)(iv)
  5. The quality unit lacked written responsibilities and did not provide effective oversight, and written procedures were not followed.

    21 CFR 211.22(a) and (d)
  6. The firm denied access to its registered suite for three days and falsely stated it did not perform CGMP drug testing, delaying the inspection.

    section 501(j) of the FD&C Act, 21 U.S.C. 351(j)

What FDA wants

Respond in writing within 15 working days with corrective actions and preventive measures; if actions cannot be completed in that time, state the reasons and a completion schedule. Notify FDA before resuming any drug testing at this or another location.

Who should pay attention

  • drug manufacturers that use contract testing labs
  • sterile injectable drug producers
  • quality teams relying on outsourced laboratory data

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk